<DOC>
	<DOCNO>NCT02474134</DOCNO>
	<brief_summary>The purpose study compare safety , tolerability , blood level two interferon beta-1b product , Betaferon PF530 , healthy volunteer .</brief_summary>
	<brief_title>Comparison Study PF530 Betaferon Healthy Subjects</brief_title>
	<detailed_description>This double-blind , randomise , two-treatment cross-over study healthy adult subject compare safety , tolerability , pharmacokinetics pharmacodynamics PF530 Betaferon . Half subject randomise receive PF530 first Betaferon second , half randomise receive drug reverse sequence . Each study participant complete two 7-day study period ( Period 1 Period 2 ) , separate 14-day washout period . In Part I study , 12 subject enrol initial assessment . In Part II , 36 additional subject may enrol .</detailed_description>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Interferon-beta</mesh_term>
	<mesh_term>Interferon beta-1b</mesh_term>
	<criteria>Females childbearing potential must agree use two effective method birth control , practice complete abstinence , confirm sterilization monogamous male partner Males must document vasectomy , practice complete abstinence use condom refrain sperm . Participant free clinically significant illness disease determine medical surgical history , physical examination , 12lead electrocardiogram ( ECG ) clinical laboratory assessment . Able understand sign write Informed Consent Form Female subject pregnant lactating . History significant cardiovascular , hepatic , renal , pulmonary , hematologic , gastrointestinal , endocrine , immunologic , dermatologic , neurologic , metabolic , psychological , musculoskeletal disease malignancy unless deem clinically significant Principal Investigator . Previous treatment interferon product , include investigational use . Participants history malignant disease , include solid tumour hematologic malignancy ( except basal cell squamous cell carcinoma skin completely excise consider cure ) . Positive screen test human immunodeficiency virus ( HIV ) . Positive screen test hepatitis C antibody ( HCV Ab ) current hepatitis B infection ( define positive hepatitis surface antigen [ HBsAg ] Screening ) . Participants immunity hepatitis B ( define negative HBsAg positive hepatitis B surface antibody [ HBsAb ] ) eligible participate study . History epilepsy , seizure disorder unexplained blackout . History hypersensitivity intolerance paracetamol nonsteroidal antiinflammatory drug ( NSAID ) would preclude use least 1 study . History severe allergic anaphylactic reaction know allergy component interferon Î²1b formulation . History drug alcohol abuse less equal 12 month prior Screening . History tobacco use less equal 6 month prior Screening . A positive test drug abuse alcohol Screening prior dose . Unwilling unable abstain alcohol 7 day prior dose endofstudy assessment . Use prescription medication , overthecounter medication , herbal supplements/products Screening throughout study , unless approve Principal Investigator Sponsor .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>November 2015</verification_date>
</DOC>